Last reviewed · How we verify
Nitroderm patch
At a glance
| Generic name | Nitroderm patch |
|---|---|
| Sponsor | Rabin Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Optimized Strict Fluid Management Helps Improve Endpoints After Liver Dissection (NA)
- Effect of Glyceroltrinitrate on Human Energy Expenditure and Brown Adipose Tissue Thermogenesis (EARLY_PHASE1)
- NICardipine for Fast Achievement of Systolic BP Targets in ICH (PHASE4)
- Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer. (NA)
- Flushing Reduction Associated With Nitrates (PHASE2)
- Coronary Microvascular Function and CT Coronary Angiography (CorCTCA) (NA)
- Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial). (PHASE4)
- BIOTRONIK Orsiro Pre-Marketing Registration (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nitroderm patch CI brief — competitive landscape report
- Nitroderm patch updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI